Drug Overview: Eligard

  • ID: 4462183
  • Drug Pipelines
  • 9 pages
  • Datamonitor Healthcare
1 of 3
Drug Overview

Eligard (leuprolide; Astellas/Tolmar Pharmaceuticals) is a gonadotropin-releasing hormone (GnRH) receptor agonist which acts on the pituitary gland to stimulate luteinizing hormone (LH) release, resulting in a temporary surge in serum testosterone levels known as "flare." Persistent use of GnRH agonists over time causes downregulation of GnRH receptors in the pituitary gland, generating a significant reduction in LH and follicle-stimulating hormone secretion. This has the effect of complete shutdown of testosterone production in the testes, resulting in chemical castration.
Note: Product cover images may vary from those shown
2 of 3
Product Profiles
Eligard: Prostate cancer

List of Figures
Figure 1: Eligard sales for prostate cancer across the US, Japan, and five major EU markets, by country, 2017-26

List of Tables
Table 1: Eligard sales for prostate cancer across the US, Japan, and five major EU markets, by country ($m), 2017-26
Note: Product cover images may vary from those shown
3 of 3

Loading
LOADING...

4 of 3
Note: Product cover images may vary from those shown
Adroll
adroll